Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma
Currently-available therapies for newly-diagnosed pediatric and adolescent patients with Hodgkin lymphoma result in >95% survival at 5 years. Long-term survivors may suffer from long-term treatment-related side effects, however, so the past 20 years have seen clinical trials for children and...
Main Authors: | Valli De Re, Ombretta Repetto, Lara Mussolin, Giulia Brisotto, Caterina Elia, Egesta Lopci, Emanuele S. G. d’Amore, Roberta Burnelli, Maurizio Mascarin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.965803/full |
Similar Items
-
Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer
by: Valli De Re, et al.
Published: (2020-06-01) -
Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin’s Lymphoma
by: Valli De Re, et al.
Published: (2023-12-01) -
Linfoma de Hodgkin em baixa faixa etária: relato de dois casos Hodgkin's lymphoma in young children: two cases report
by: Silvia M. Luporini, et al.
Published: (2006-12-01) -
A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma
by: Valli De Re, et al.
Published: (2021-05-01) -
Study of TRADD Methylation Pattern in Patients with Hodgkin\'s Lymphoma EBV Positive
by: B Ahmadi, et al.
Published: (2019-01-01)